Core Insights - Enlivex Therapeutics is raising $212 million in a private placement to become the first publicly traded U.S. company to adopt a blockchain-based prediction markets token, RAIN, as its main treasury reserve asset [1][3] - The RAIN token operates on the Arbitrum blockchain, enabling users to create and trade prediction markets on real-world events [1][2] - Enlivex plans to use the majority of the funds raised to purchase RAIN tokens, viewing the prediction markets space as a strategic growth area [3] Company Developments - Enlivex has a market cap of $22 million on Nasdaq and aims to integrate RAIN tokens into its treasury management strategy [3] - The company is continuing clinical trials for its lead drug candidate, Allocetra, which targets osteoarthritis, a condition affecting over 30 million Americans [4] - Matteo Renzi, former Prime Minister of Italy, is expected to join Enlivex's board following the completion of the deal on November 25 [5] Financial Aspects - The transaction is priced at $1 per share, representing an 11.5% premium over Enlivex's last trading price [5] - Last year, Enlivex's board approved the purchase of up to $1 million in Bitcoin as part of its cash-management strategy [5]

Listing Announcement - Coinbase to list Boundless (ZKC) [1] - Spot trading for ZKC-USD pair to launch on September 15, 2025, contingent on sufficient liquidity [1] - ZKC token will be labeled "Experimental" [1] Project Information - Boundless is a decentralized protocol [1]

Industry Trend - Decentralized protocol rails will host or connect all applications in the next 10 years [1] - Ethereum is at the forefront of this trend [1] Investment Opportunity - SharpLink offers investors the best way to capitalize on the Ethereum trend [1]